ClinicalTrials.gg

Program

Roflumilast

Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “Roflumilast Foam 0.3%”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.

Furthest: phase 4, since Mar 30, 201161 company-led studies, 3 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca340 open or runningphase 4since Mar 30, 2011Jun 9, 2003none ahead
Arcutis Biotherapeutics181 open or runningphase 3since Dec 23, 2019Dec 29, 2017Apr 27, 2028phase 3 · NCT07916480
Huadong Medicine31 open or runningphase 3since Sep 30, 2024Sep 30, 2024Jun 30, 2027phase 3 · NCT07683806
FLUIDDA nv20 open or runningphase 4since Nov 21, 2011Nov 21, 2011none ahead
Integrative Skin Science and Research11 open or runningphase 4since Apr 23, 2026Apr 23, 2026Aug 2027phase 4 · NCT07560618
Padagis10 open or runningphase 3since Feb 28, 2023Feb 28, 2023none ahead
Sino Biopharmaceutical10 open or runningphase 2since Jan 25, 2016Jan 25, 2016none ahead
Takeda10 open or runningphase 1since Mar 4, 2014Mar 4, 2014none ahead

Also a collaborator on its studies: Tanabe Pharma, fougera-pharmaceuticals-inc and Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Nov 17, 2003.

  1. Feb 25, 2020Phase 3 study in Chronic Plaque PsoriasisArcutis Biotherapeutics · NCT04286607 · 337 enrolled · United States, Canada, Dominican Republic
  2. Nov 30, 2020Phase 2 study in PsoriasisArcutis Biotherapeutics · NCT04655313 · 20 enrolled · United States, Canada, Dominican Republic
  3. Feb 5, 2021Phase 2 study in PsoriasisArcutis Biotherapeutics · NCT04746911 · 10 enrolled · United States, Canada, Dominican Republic
  4. Feb 24, 20212 phase 3 studies in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04773600, NCT04773587
  5. Mar 16, 2021Phase 3 study in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04804605 · 1,220 enrolled · United States, Canada
  6. Apr 11, 2021Phase 3 study in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04845620 · 652 enrolled · United States, Canada
  7. Aug 25, 2021Phase 3 study in Scalp PsoriasisArcutis Biotherapeutics · NCT05028582 · 432 enrolled · United States, Canada
  8. Feb 28, 2023Padagis's first study: phase 3 study in Plaque PsoriasisNew to PadagisPadagis · NCT05763082 · 416 enrolled · United States
  9. Sep 30, 2024Huadong Medicine's first study: phase 3 study in Dermatitis, AtopicNew to Huadong MedicineHuadong Medicine · NCT06631170 · 354 enrolled · China
  10. Oct 9, 2024Phase 3 study in Plaque PsoriasisHuadong Medicine · NCT06648772 · 190 enrolled · China
  11. May 5, 2025Phase 2 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT06998056 · 101 enrolled · United States, Canada, Dominican Republic
  12. Apr 23, 2026Integrative Skin Science and Research's first study: phase 4 study in Dermatitis, AtopicNew to Integrative Skin Science and ResearchIntegrative Skin Science and Research · NCT07560618 · 40 planned · United States
  13. Jun 22, 2026Phase 3 study in Dermatitis, SeborrheicHuadong Medicine · NCT07683806 · 309 planned · China
  14. Oct 30, 2026Phase 3 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT07916480 · 415 planned · United States

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Dermatitis, SeborrheicHuadong Medicine · NCT07683806
  2. Aug 2027Primary completion: phase 4 study in Dermatitis, AtopicIntegrative Skin Science and Research · NCT07560618
  3. Apr 27, 2028Primary completion: phase 3 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT07916480

TargetBeta

“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 5 targets

ProgramCompanyFurthest phaseStudies
ensifentrineruleMerckphase 317

Studies

The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07916480Dermatitis, Atopic · United States3RecruitingArcutis BiotherapeuticsApr 27, 2028415
NCT07683806Dermatitis, Seborrheic · China3Not yet recruitingHuadong MedicineJun 30, 2027309
NCT07560618Dermatitis, Atopic · United States4RecruitingIntegrative Skin Science and ResearchAug 202740
NCT06998056Dermatitis, Atopic · United States, Canada, Dominican Republic2CompletedArcutis BiotherapeuticsDec 4, 2025101
NCT06648772Plaque Psoriasis · China3CompletedHuadong MedicineOct 13, 2025190
NCT06631170Dermatitis, Atopic · China3CompletedHuadong MedicineMay 27, 2025354
NCT05763082Plaque Psoriasis · United States3CompletedPadagisAug 8, 2023416
NCT05028582Scalp Psoriasis · United States, Canada3CompletedArcutis BiotherapeuticsJun 3, 2022432
NCT04845620Atopic Dermatitis Eczema · United States, Canada3CompletedArcutis BiotherapeuticsJun 1, 2023652
NCT04804605Atopic Dermatitis Eczema · United States, Canada3CompletedArcutis BiotherapeuticsMay 28, 20241,220
NCT04773600Atopic Dermatitis Eczema · United States, Canada3CompletedArcutis BiotherapeuticsSep 29, 2022683
NCT04773587Atopic Dermatitis Eczema · United States, Canada3CompletedArcutis BiotherapeuticsAug 30, 2022654
NCT04746911Psoriasis · United States, Canada, Dominican Republic2CompletedArcutis BiotherapeuticsMay 11, 202210
NCT04655313Psoriasis · United States, Canada, Dominican Republic2CompletedArcutis BiotherapeuticsJan 12, 202220
NCT04286607Chronic Plaque Psoriasis · United States, Canada, Dominican Republic3CompletedArcutis BiotherapeuticsJan 22, 2024337
NCT04279119Plaque Psoriasis · United States1CompletedArcutis BiotherapeuticsMar 25, 202126
NCT04211389Chronic Plaque Psoriasis · United States, Canada3CompletedArcutis BiotherapeuticsNov 23, 2020442
NCT04211363Chronic Plaque Psoriasis · United States, Canada3CompletedArcutis BiotherapeuticsNov 16, 2020439
NCT04156191Dermatitis, Atopic · United States1CompletedArcutis BiotherapeuticsMay 2, 2023101
NCT03916081Dermatitis, Atopic · United States, Canada2CompletedArcutis BiotherapeuticsNov 4, 2019136
NCT03764475Plaque Psoriasis · United States, Canada2CompletedArcutis BiotherapeuticsOct 8, 2020332
NCT03638258Plaque Psoriasis · United States, Canada2CompletedArcutis BiotherapeuticsMay 29, 2019331
NCT03392168Psoriasis · United States, Canada2CompletedArcutis BiotherapeuticsMay 2, 201891
NCT02671942Pulmonary Disease, Chronic Obstructive · China2TerminatedSino BiopharmaceuticalJun 13, 201855
NCT02451540Pulmonary Disease, Chronic Obstructive · Belgium2TerminatedFLUIDDA nvAug 31, 201713
NCT02165826Pulmonary Disease, Chronic Obstructive · Slovakia3CompletedAstraZenecaSep 1, 20151,323
NCT02079844Schizophrenia · United Kingdom1CompletedTakedaJun 201520
NCT02051335Memory Disorders · United Kingdom1CompletedAstraZenecaMay 201427
NCT01856764Dermatitis, Atopic · Germany2CompletedAstraZenecaMar 201440
NCT01765192Asthma · Germany, Hungary, South Africa2CompletedAstraZenecaOct 201364
NCT01703260Nonalcoholic Steatohapatitis · United States2TerminatedAstraZenecaSep 201420
NCT01664624Diabetes Mellitus, Type 2 · United States1CompletedAstraZenecaNov 201240
NCT01509677Pulmonary Disease, Chronic Obstructive · Denmark, Germany, Poland and more3CompletedAstraZenecaFeb 1, 2016158
NCT01480661Pulmonary Disease, Chronic Obstructive · Belgium4CompletedFLUIDDA nvApr 201341
NCT01473758Pulmonary Disease, Chronic Obstructive · United Kingdom2TerminatedAstraZenecaMar 201481
NCT01443845Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more4CompletedAstraZenecaNov 30, 20152,354
NCT01365533Allergic Asthma · Canada2CompletedAstraZenecaJul 200548
NCT01354782Pulmonary Disease, Chronic Obstructive · China1CompletedAstraZenecaJun 201132
NCT01329029Pulmonary Disease, Chronic Obstructive · Australia, Austria, Belgium and more4CompletedAstraZenecaMar 20141,945
NCT01313494Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Singapore3CompletedAstraZenecaMay 2012626
NCT01140542Diabetes Mellitus, Type 22CompletedAstraZenecaNov 2007487
NCT00940329Healthy · Germany1CompletedAstraZenecaJul 200427
NCT00746434Plaque Psoriasis2WithdrawnAstraZenecaJun 20090
NCT00746382Dermatitis2WithdrawnAstraZenecaJun 20090
NCT00430729Pulmonary Disease, Chronic Obstructive · Australia, Austria, Canada and more3CompletedAstraZeneca1,100
NCT00424268Pulmonary Disease, Chronic Obstructive · Austria, France, Germany and more3CompletedAstraZenecaJan 2008743
NCT00313209Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Canada and more3CompletedAstraZenecaJul 2007933
NCT00297115Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more3CompletedAstraZenecaApr 20081,568
NCT00297102Pulmonary Disease, Chronic Obstructive · United States, Australia, Austria and more3CompletedAstraZenecaJul 20081,523
NCT00246935Pulmonary Disease, Chronic Obstructive · Japan3CompletedAstraZenecaJan 2007150
NCT00246922Asthma · Japan3CompletedAstraZenecaJan 1, 2007150
NCT00242320Pulmonary Disease, Chronic Obstructive · Hong Kong, Korea, Republic of, Malaysia and more3CompletedAstraZenecaMay 2007551
NCT00242307Asthma · Japan3CompletedAstraZenecaSep 1, 2006450
NCT00242294Pulmonary Disease, Chronic Obstructive · Japan3CompletedAstraZenecaSep 2006570
NCT00163527Asthma · United States, Austria, Croatia and more3CompletedAstraZenecaNov 20052,054
NCT00163475Asthma · Australia, Belgium, France and more3CompletedAstraZenecaAug 2005511
NCT00108823Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more3CompletedAstraZeneca550
NCT00076089Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more3CompletedAstraZenecaDec 20051,100
NCT00076076Asthma · United States, Russian Federation, Ukraine3CompletedAstraZeneca822
NCT00073177Asthma · United States, Argentina, Colombia and more3CompletedAstraZeneca819

How it is read

Names in the registry

  • “Roflumilast”, 37 entries
  • “Roflumilast Cream 0.15%”, 5 entries
  • “Roflumilast Cream 0.3%”, 3 entries
  • “Roflumilast Foam 0.3%”, 2 entries
  • “ARQ-151 cream 0.3%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.